NextCure, Inc.

NXTCSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1661059

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	—	—	—	—	$22.4M
Research and Development Expense	$41.5M	$47.9M	$54.2M	$50.2M	$46.6M
Operating Expenses	$59.7M	$67.6M	$75.9M	$70.8M	$63.6M
Operating Income (Loss)	-$59.7M	-$67.6M	-$75.9M	-$70.8M	-$41.2M
Interest Expense	—	—	—	—	—
Other Nonoperating Income (Expense)	$4.1M	$4.9M	$1.2M	$1.4M	$4.6M
Income Tax Expense (Benefit)	$0.00	—	—	—	—
Net Income (Loss) Attributable to Parent

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$80.9M	$128.0M	$184.2M	$242.4M	$306.6M
Assets, Current	$71.8M	$112.7M	$164.0M	$227.8M	$288.0M
Cash and Cash Equivalents, at Carrying Value	$27.7M	$13.1M	$26.6M	$12.3M	$32.8M
Liabilities	$15.4M	$13.6M	$16.6M	$9.0M	$12.9M
Liabilities, Current	$9.6M	$6.9M	$9.1M	$6.6M	$10.3M
Long-term Debt	—	—	—	$0.00	$0.00
Accounts Payable, Current	$5.4M	$2.3M	$4.3M	$1.9M	$3.9M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$40.8M	-$53.0M	-$53.9M	-$57.3M	-$45.0M
Net Cash Provided by (Used in) Investing Activities	$55.3M	$39.3M	$68.0M	$36.6M	$43.5M
Net Cash Provided by (Used in) Financing Activities	$144.0K	$154.0K	$200.0K	-$3.3M	-$1.4M
Payments to Acquire Property, Plant, and Equipment	$474.0K	$820.0K	$2.1M	$2.4M	$7.1M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)